The Combined Utility of Angio-CT and MRI in Managing Chronic Musculoskeletal Pain: a Prospective Study to Evaluate the Efficacy of Transarterial Microembolization

Launched by TRI-SERVICE GENERAL HOSPITAL · Jul 17, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called transarterial microembolization (TAME) for people suffering from chronic musculoskeletal pain, particularly in the shoulder and knee. This treatment is designed for patients who haven’t found relief through traditional methods like medications or physical therapy and are not candidates for surgery. The study aims to improve how doctors plan and perform this treatment by using advanced imaging techniques, such as MRI and CT scans, to get a clearer picture of the pain areas. By combining these imaging methods, the goal is to help doctors make better decisions during the procedure and ultimately achieve better outcomes for patients.

To participate in this study, individuals should have ongoing pain in their shoulder or knee, which has lasted for more than three months and hasn’t improved with standard treatments. However, pregnant individuals, those with bleeding disorders, infections, tumors, or allergies to certain imaging materials cannot join. If eligible, participants can expect to undergo imaging tests and receive the TAME treatment while being closely monitored by medical professionals. This trial is an exciting opportunity to explore a potential new way to relieve chronic pain for those who have struggled with it for a long time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with chronic musculoskeletal shoulder or knee joint pain in our hospital, including degenerative knee arthritis, adhesive capsulitis of the shoulder, and those confirmed by physical examination or ultrasound-guided injection to have tendinopathy or ligamentopathy, who have failed drug therapy, rehabilitation, or injection treatments, with a duration of symptoms greater than three months, are the target population of this study.
• Exclusion Criteria:
• • Pregnancy, coagulation disorders, symptoms of relevant local infections or tumors, and patients allergic to contrast agents. Patients must have complete medical records; those who do not meet the inclusion criteria will be excluded.